Kairos Pharma Ltd. Share Price Today: Live Updates & Key Insights
Kairos Pharma Ltd. share price today is $0.5995, up -2.52%. The stock opened at $0.6027 against the previous close of $0.615, with an intraday high of $0.62 and low of $0.554.
Kairos Pharma Ltd. Share Price Chart
Kairos Pharma Ltd.
Kairos Pharma Ltd. Share Price Performance
Kairos Pharma Ltd. Institutional Holdings
Kairos Pharma Ltd. Market Status
Kairos Pharma Ltd. Fundamentals
Market Cap 12.48 M
PB Ratio 1.6708
PE Ratio 0.0
Enterprise Value 9.73 M
Total Assets 6.22 M
Volume 216437
Kairos Pharma Ltd. Company Financials
About Kairos Pharma Ltd. & investment objective
Company Information Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The company develops KROS 101, an orally available glucocorticoid-induced tumor necrosis factor receptor (GITR) ligand small-molecule antagonist to deplete regulatory T cells (Tregs) and activate effector T cells to augment the antitumor immune response for the treatment of patients with cancer, and a systemic immune modulator to address immunosuppressive activity of solid cancers; KROS 102, a GITR antagonist to increase the inhibitory regulatory Tregs functions; KROS 201 that activates the T cells using dendritic cells for the treatment of patients with glioblastoma; KROS 301, a tumor-targeting small molecule and checkpoint inhibitor with mechanisms of action resulting from blocking intranuclear localization of RelA, a key component of the NF-KB pathway, as well as targets tumor cells in RelA/p65 biomarker positive solid tumors; and KROS 401, a tumor microenvironment immune modulator and cyclic peptide inhibitor of IL-4 and IL-13 reversing tumor associated macrophage inhibition, and blocks the IL4/IL13 cytokine immune receptors for triple negative breast cancer. It also develops ENV 105, an antibody therapeutic for the prostate cancer patients resistant to androgen-targeted therapy, which is in Phase 2 clinical trial; and ENV 205, an antibody fragment that targets mitochondrial DNA. The company was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. Kairos Pharma, Ltd. was incorporated in 2013 and is based in Los Angeles, California.
Organisation Biotechnology
Employees 1
Industry Biotechnology
CEO Dr. John S. Yu M.D., Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:
Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*
Take your next step
Kairos Pharma Ltd. FAQs
What is the share price of Kairos Pharma Ltd. today?
The current share price of Kairos Pharma Ltd. is $0.5995.
Can I buy Kairos Pharma Ltd. shares in India?
Yes, Indian investors can buy Kairos Pharma Ltd. shares by opening an international trading and demat account with Motilal Oswal.
How to buy Kairos Pharma Ltd. shares in India?
You can easily invest in Kairos Pharma Ltd. shares from India by:
- Direct Investment:
Opening an international trading account with Motilal Oswal which includes KYC verification in the US. Your account gets activated in a few minutes to a few hours, after which you can start adding funds in USD balance to buy Kairos Pharma Ltd. shares. - Indirect Investment:
Under this form of investment, you can choose either a Mutual Fund (MF) or an Exchange-Traded Fund (ETF) that invests in global shares and start investing in shares of Kairos Pharma Ltd..
Can I buy fractional shares of Kairos Pharma Ltd.?
Yes, many platforms allow you to buy fractional shares starting from as low as $1.
What is the market capitalization value of Kairos Pharma Ltd.?
Kairos Pharma Ltd. has a market cap of $12.48 M.
In which sector does Kairos Pharma Ltd. belong?
Kairos Pharma Ltd. operates in the Biotechnology sector.
What documents are required to invest in Kairos Pharma Ltd. stocks?
To invest, you typically need:
What is the PE and PB ratio of Kairos Pharma Ltd.?
The PE ratio of Kairos Pharma Ltd. is N/A and the PB ratio is 1.67.